Protalix BioTherapeutics, Inc. (PLX)

Latest Insider Confidence Score

2025Q4

51.3
Bullish

Company insider confidence (by quarter)

2005Q4 2025Q4

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Sheratzki Eyal — 14,466,319 Jan 5, 2007
Camber Capital Management LP 10% Owner 10,775,000 Dec 6, 2016
Frost Phillip Md Et Al 10% Owner 7,610,167 Sep 11, 2009
Frost Gamma Investments Trust 10% Owner 7,610,167 Sep 11, 2009
Marathon Investments Ltd. — 6,556,381 Jan 10, 2007

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Dec 19, 2025 Dec 23, 2025 Bashan Dror CEO Buy 82.5 +56,000 2.26% ✗ $101.4K
Nov 18, 2025 Nov 19, 2025 Bar-Shalev Amos Director Sell 27.5 -168 -2.19% ✗ $314.2
Sep 3, 2025 Sep 4, 2025 Melincoff Gwen A Director Neutral 90.0 +7,500 100.00% ✗ -
Sep 3, 2025 Sep 4, 2025 Forster Eliot Director Neutral 90.0 +7,500 100.00% ✗ -
Sep 3, 2025 Sep 4, 2025 Boudes Pol F Director Neutral 90.0 +7,500 18750.00% ✗ -
Sep 3, 2025 Sep 4, 2025 Schwartz Aharon Director Neutral 77.5 +7,500 2.48% ✗ -
Sep 3, 2025 Sep 4, 2025 Elze Christian Director Neutral 90.0 +7,500 100.00% ✗ -
Sep 3, 2025 Sep 4, 2025 Ben Zvi Shmuel Director Neutral 90.0 +7,500 100.00% ✗ -
Sep 3, 2025 Sep 4, 2025 Bar-Shalev Amos Director Neutral 90.0 +7,500 4464.29% ✗ -
Sep 3, 2025 Sep 4, 2025 Naos Yaron Sr. VP, Operations Neutral 90.0 +25,000 12.02% ✗ -
Sep 3, 2025 Sep 4, 2025 Bashan Dror CEO Neutral 85.0 +195,000 8.55% ✗ -
Aug 25, 2025 Mamlok Gilad CFO Neutral 52.5 - 0.00% ✗ -
Jun 10, 2025 Aug 12, 2025 Schwartz Aharon Director Buy 95.0 +129,000 74.14% ✗ $205.9K
Jul 3, 2025 Elze Christian Director Neutral 52.5 - 0.00% ✗ -
Sep 23, 2024 Nov 5, 2024 Rubin Eyal CFO Neutral 90.0 +90,909 15.95% ✗ -
Sep 23, 2024 Sep 24, 2024 Rubin Eyal CFO Neutral 90.0 +99,010 17.37% ✗ -
Sep 23, 2024 Sep 24, 2024 Naos Yaron Sr. VP, Operations Neutral 52.5 - 0.00% ✗ -
Apr 1, 2024 Apr 3, 2024 Bashan Dror CEO Neutral 90.0 +263,960 13.08% ✗ -
Oct 19, 2023 Oct 20, 2023 Bashan Dror CEO Buy 95.0 +64,516 94.88% ✗ $90.5K
Sep 29, 2023 Oct 3, 2023 Boudes Pol F Director Neutral 52.5 - 0.00% ✗ -
Sep 29, 2023 Oct 3, 2023 Melincoff Gwen A Director Neutral 52.5 - 0.00% ✗ -
Sep 29, 2023 Oct 3, 2023 Bar-Shalev Amos Director Neutral 52.5 - 0.00% ✗ -
Sep 29, 2023 Oct 3, 2023 Ben Zvi Shmuel Director Neutral 52.5 - 0.00% ✗ -
Sep 29, 2023 Oct 3, 2023 Schwartz Aharon Director Neutral 52.5 - 0.00% ✗ -
Sep 14, 2023 Sep 15, 2023 Forster Eliot Director Neutral 52.5 - 0.00% ✗ -
Sep 15, 2023 Forster Eliot Director Neutral 52.5 - 0.00% ✗ -
Aug 15, 2023 Aug 17, 2023 Bashan Dror CEO Neutral 90.0 +800,000 69.36% ✗ -
Aug 15, 2023 Aug 17, 2023 Rubin Eyal CFO Neutral 90.0 +201,903 54.85% ✗ -
Aug 15, 2023 Aug 17, 2023 Hayon Yael VP, Research & Development Neutral 90.0 +35,115 100.00% ✗ -
Aug 15, 2023 Aug 17, 2023 Naos Yaron Sr. VP, Operations Neutral 90.0 +187,344 910.10% ✗ -
Jan 3, 2023 Jan 5, 2023 Schwartz Aharon Director Buy 95.0 +110,000 171.88% ✗ $155.8K
Sep 7, 2022 Sep 9, 2022 Ben Zvi Shmuel Director Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Naos Yaron Sr. VP, Operations Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Hayon Yael VP, Research & Development Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Rubin Eyal CFO Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Bashan Dror CEO Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Schwartz Aharon Director Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Bronfeld Zeev Director Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Bar-Shalev Amos Director Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Melincoff Gwen A Director Neutral 52.5 - 0.00% ✗ -
Sep 7, 2022 Sep 9, 2022 Boudes Pol F Director Neutral 52.5 - 0.00% ✗ -
Jun 30, 2022 Jul 5, 2022 Ben Zvi Shmuel Director Neutral 52.5 - 0.00% ✗ -
Jul 5, 2022 Ben Zvi Shmuel Director Neutral 52.5 - 0.00% ✗ -
Apr 11, 2022 Apr 13, 2022 Bashan Dror CEO Buy 90.0 +68,000 6.26% ✗ $102K
Feb 25, 2022 Feb 28, 2022 Rubin Eyal CFO Neutral 90.0 +121,951 49.54% ✗ -
Feb 25, 2022 Feb 28, 2022 Bashan Dror CEO Neutral 90.0 +637,531 142.33% ✗ -
Jun 2, 2021 Jun 3, 2021 Dexcel Pharma Technologies Ltd. 10% Owner Sell 17.5 -918,717 -20.16% ✗ $2.1M
Feb 16, 2021 Dexcel Pharma Technologies Ltd. 10% Owner Neutral 52.5 - 0.00% ✗ -
Aug 11, 2020 Aug 14, 2020 Rubin Eyal CFO Neutral 90.0 +246,146 100.00% ✗ -
Aug 11, 2020 Aug 14, 2020 Bashan Dror CEO Neutral 90.0 +447,927 100.00% ✗ -
Aug 11, 2020 Aug 13, 2020 Rubin Eyal CFO Neutral 90.0 +246,146 100.00% ✗ -
Aug 11, 2020 Aug 13, 2020 Bashan Dror CEO Neutral 90.0 +447,927 100.00% ✗ -
Aug 11, 2020 Aug 13, 2020 Naos Yaron Sr. VP, Operations Neutral 52.5 - 0.00% ✗ -
Jul 5, 2020 Jul 8, 2020 Hayon Yael VP, Research & Development Neutral 52.5 - 0.00% ✗ -
Jul 8, 2020 Hayon Yael President Neutral 52.5 - 0.00% ✗ -
Jun 7, 2020 Jun 8, 2020 Almon Einat Brill SVP, Chief Development Officer Neutral 52.5 - 0.00% ✗ -
Apr 7, 2020 Apr 13, 2020 Schwartz Aharon Director Buy 95.0 +64,000 100.00% ✗ $155.3K
Feb 3, 2020 Feb 5, 2020 Bronfeld Zeev Director Neutral 52.5 - 0.00% ✗ -
Jan 20, 2020 Jan 22, 2020 Granot David Director Neutral 52.5 - 0.00% ✗ -
Jan 20, 2020 Jan 22, 2020 Bar-Shalev Amos Director Neutral 52.5 - 0.00% ✗ -
Jan 20, 2020 Jan 22, 2020 Schwartz Aharon Director Neutral 52.5 - 0.00% ✗ -
Jan 20, 2020 Jan 22, 2020 Boudes Pol F Director Neutral 52.5 - 0.00% ✗ -
Jan 20, 2020 Jan 22, 2020 Melincoff Gwen A Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2020 Melincoff Gwen A Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2020 Boudes Pol F Director Neutral 52.5 - 0.00% ✗ -
Sep 22, 2019 Sep 24, 2019 Rubin Eyal CFO Neutral 52.5 - 0.00% ✗ -
Sep 24, 2019 Rubin Eyal CFO Neutral 52.5 - 0.00% ✗ -
Jun 30, 2019 Jul 2, 2019 Bashan Dror CEO Neutral 52.5 - 0.00% ✗ -
Jul 2, 2019 Bashan Dror CEO Neutral 52.5 - 0.00% ✗ -
Sep 13, 2018 Sep 14, 2018 Maimon Yossi CFO Neutral 52.5 - 0.00% ✗ -
Sep 13, 2018 Sep 14, 2018 Almon Einat Brill SVP, Product Development Neutral 52.5 - 0.00% ✗ -
Sep 13, 2018 Sep 14, 2018 Naos Yaron Sr. VP, Operations Neutral 52.5 - 0.00% ✗ -
Sep 13, 2018 Sep 14, 2018 Manor Moshe CEO Neutral 52.5 - 0.00% ✗ -
Sep 13, 2018 Sep 14, 2018 Shaaltiel Yoseph Executive VP, R&D Neutral 52.5 - 0.00% ✗ -
Aug 13, 2018 Granot David Director Neutral 52.5 - 0.00% ✗ -
Jun 8, 2018 Naos Yaron Sr. VP, Operations Neutral 52.5 - 0.00% ✗ -
May 16, 2017 May 16, 2017 Manor Moshe CEO Buy 91.3 +50,000 100.00% ✗ $40.5K
Dec 2, 2016 Dec 6, 2016 Camber Capital Management LLC 10% Owner Sell 20.0 -2,500,000 -18.83% ✗ $792K
Sep 15, 2016 Sep 16, 2016 Shaaltiel Yoseph Executive VP, R&D Neutral 52.5 - 0.00% ✗ -
Dec 14, 2015 Dec 15, 2015 Maimon Yossi CFO Buy 85.0 +10,000 5.41% ✗ $7.8K
Oct 19, 2015 Oct 20, 2015 Camber Capital Management LLC 10% Owner Buy 100.0 +4,000,423 43.13% ✗ $4M
Oct 20, 2015 Camber Capital Management LLC 10% Owner Neutral 52.5 - 0.00% ✗ -
Mar 23, 2015 May 7, 2015 Maimon Yossi CFO Neutral 52.5 - 0.00% ✗ -
Mar 23, 2015 May 7, 2015 Shaaltiel Yoseph Executive VP, R&D Neutral 52.5 - 0.00% ✗ -
Mar 23, 2015 May 7, 2015 Palash Tzvi COO Neutral 52.5 - 0.00% ✗ -
Mar 23, 2015 May 7, 2015 Almon Einat Brill SVP, Product Development Neutral 52.5 - 0.00% ✗ -
Nov 17, 2014 Schwartz Aharon Director Neutral 52.5 - 0.00% ✗ -
Sep 29, 2014 Nov 3, 2014 Manor Moshe CEO Neutral 52.5 - 0.00% ✗ -
Nov 3, 2014 Manor Moshe CEO Neutral 52.5 - 0.00% ✗ -
Oct 2, 2014 Oct 6, 2014 Bronfeld Zeev Director Neutral 27.5 -1,185,576 -35.41% ✗ -
Sep 16, 2014 Sep 18, 2014 Bronfeld Zeev Director Neutral 27.5 -6,718,262 -66.74% ✗ -
Sep 16, 2014 Sep 18, 2014 Bio-Cell Ltd 10% Owner Neutral 27.5 -8,556,371 -85.00% ✗ -
Aug 13, 2014 Aug 15, 2014 Bronfeld Zeev Director Sell 15.0 -4,400,000 -30.42% ✗ $10.9M
Aug 13, 2014 Aug 15, 2014 Bio-Cell Ltd 10% Owner Sell 15.0 -4,400,000 -30.42% ✗ $10.9M
Jul 24, 2014 Jul 24, 2014 Yanai Shlomo Director Neutral 52.5 - 0.00% ✗ -
Jul 24, 2014 Yanai Shlomo Director Neutral 52.5 - 0.00% ✗ -
Aug 14, 2013 Aug 16, 2013 Akirov Alfred Director Sell 20.0 -112,330 -2.23% ✗ $567.6K
Mar 12, 2013 Mar 14, 2013 Akirov Alfred Director Sell 47.5 -10,000 -0.20% ✗ $57K
Mar 8, 2013 Mar 12, 2013 Akirov Alfred Director Sell 47.5 -35,198 -0.09% ✗ $203.8K
Mar 6, 2013 Mar 8, 2013 Akirov Alfred Director Sell 40.0 -13,135 -0.26% ✗ $75K